Lirum Therapeutics (Lirum Therapeutics) Ending Cash Position : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Ending Cash Position?

Lirum Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 was $0.00 Mil.

Lirum Therapeutics's quarterly Ending Cash Position declined from Dec. 2022 ($0.17 Mil) to Sep. 2023 ($0.00 Mil) but then stayed the same from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Lirum Therapeutics's annual Ending Cash Position increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.17 Mil) and increased from Dec. 2022 ($0.17 Mil) to Dec. 2023 ($4.01 Mil).

Lirum Therapeutics Ending Cash Position Historical Data

The historical data trend for Lirum Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Ending Cash Position Chart

Lirum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Ending Cash Position

0.17

4.01

Lirum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Ending Cash Position	-	-	0.17	-	-

Lirum Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Lirum Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.174	+	3.835
	=	4.01

Lirum Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0	+	0
	=	0.00

Lirum Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Lirum Therapeutics (Lirum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

590 Madison Avenue, 21st Floor, New York, NY, USA, 10022

Website

https://www.lirumtx.com

Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines